2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Proquad Market?

The rising incidence of measles and chickenpox is expected to propel the growth of the proquad market going forward. Measles is a highly contagious viral infection characterized by fever, cough, and a red rash, preventable through vaccination, while chickenpox is a contagious disease caused by the Varicella-zoster virus, marked by an itchy blister-like rash and preventable with a vaccine. Measles and chickenpox cases are rising due to declining vaccination rates, misinformation about vaccines, increased global travel, and outbreaks in unvaccinated populations, leading to the re-emergence of these preventable diseases. Proquad, a combination vaccine for measles, mumps, rubella, and varicella (chickenpox), helps protect against these diseases by providing immunity through a single dose, reducing the risk of infection, controlling outbreaks, and ensuring comprehensive coverage to prevent complications associated with measles and chickenpox. For instance, in May 2024, according to the World Health Organization, a Switzerland-based non-profit organization, 56,634 measles cases and four deaths were officially reported across 45 out of 53 countries in the WHO European Region during the first three months of 2024. Throughout 2023, 61,070 cases and 13 deaths were reported by 41 countries. Therefore, the rising incidence of measles and chickenpox is driving the growth of the proquad market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

What is the Predicted Annual Growth Rate of theProquad Market Impact Industry Trends by 2034?

The proquad market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to established immunization schedules, combination vaccine advantages, government-supported vaccination programs, epidemic outbreaks, strong healthcare infrastructure, and regulatory approvals.

The proquad market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to population growth, improved access to healthcare, global health initiatives, rising awareness of vaccine-preventable diseases, government vaccination funding, and a growing focus on preventive healthcare. Major trends in the forecast period include global vaccination coverage, technological advancements in vaccine delivery, integration of vaccines in routine health systems, improvements in vaccine accessibility, and increased awareness of vaccine safety.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349

What New Market Trends Are Reshaping theProquad Market and Its Opportunities?

A key trend in the proquad market is the focus on expansion of vaccine administration options such as intramuscular (IM) administration to enhance convenience and consistency in immunization practices. Intramuscular (IM) administration refers to the delivery of a vaccine or medication directly into the muscle tissue, allowing for faster absorption into the bloodstream. For instance, in March 2023, Merck & Co. Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for the addition of an intramuscular (IM) administration option to the U.S. Product Insert (USPI) for its MMRV vaccine family, including ProQuad. With this approval, the MMRV family joins other commonly recommended vaccines that can be given intramuscularly. Healthcare professionals in the U.S. now have the option to administer all routinely recommended injectable pediatric vaccines in the CDC immunization schedule via the same IM route. M-M-R II, VARIVAX, and ProQuad are the only measles, mumps, rubella, and varicella vaccines approved for IM administration in the U.S. The MMRV family of vaccines is also licensed for IM use in the European Union.

Who Are the Leading Market Players Fueling Growth in the Proquad Market Trend?

Major companies operating in the proquad market are Merck and Co. Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

How is the Global Proquad Market Segemented?

The proquad market covered in this report is segmented –

1) By Indication: Measles; Mumps; Rubella; Varicella

2) By Patient Type: Pediatric Patient; Adult Patient

3) By End User: Healthcare Providers; Pharmacies; Public Health Organization

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20349&type=smp

Which Geographics are Influencing the Growth of the Proquad Market?

North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Proquad Market 2025, By The Business Research Company:

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Hepatitis B Virus (HBV) Global Market Report 2025

https://thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Global Drug Delivery Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/drug-delivery-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: